Shopping Cart
- Remove All
![TargetMol](https://www.targetmol.com/storage/error/oops.webp)
Your shopping cart is currently empty
Pack Size | Price | Availability | Quantity |
---|---|---|---|
5 mg | Inquiry | Backorder | |
50 mg | Inquiry | Backorder |
Description | BT1718 is a bicyclic peptide conjugate that targets MT1-MMP, a protease overexpressed in various advanced solid tumors such as triple-negative breast cancer (TNBC) and non-small cell lung cancer [1] [2]. By exploiting MT1-MMP, BT1718 delivers its cytotoxic payload, Mertansine, with a strong affinity characterized by a dissociation constant (K D) of 3 nM. |
In vitro | BT1718 (IC50 = 1 nM, 72 h) demonstrated cytotoxicity against HT-1080 cells in an ATP endpoint assay [2]. |
In vivo | BT1718 (10mg/kg, intravenous injection, thrice weekly) demonstrated rapid tumor clearance in a mouse xenograft model derived from EBC-1 cells positive for MT1 [2]. Furthermore, with once or twice weekly intravenous administration of BT1718 at the same dosage, complete tumor eradication was observed in a mouse xenograft model implanted with MT1 positive HT-1080 cells [2]. |
Formula | C159H218ClN31O47S5 |
Cas No. | 2227366-66-5 |
Storage | keep away from moisture Powder: -20°C for 3 years | In solvent: -80°C for 1 year |
Copyright © 2015-2024 TargetMol Chemicals Inc. All Rights Reserved.